carnitine has been researched along with Cognitive Dysfunction in 10 studies
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| "L-carnitine has been shown to exert neuroprotective effects on cerebral ischemia, mainly by improving mitochondrial function and reducing inflammation." | 8.12 | Association Between Plasma L-Carnitine and Cognitive Impairment in Patients with Acute Ischemic Stroke. ( Bu, X; Che, B; Chen, H; He, J; Ju, Z; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2022) |
| "Although l-carnitine alleviated white-matter lesions in an experimental study, the treatment effects of l-carnitine on white-matter microstructural damage and cognitive decline in hemodialysis patients are unknown." | 8.02 | Possible Neuroprotective Effects of l-Carnitine on White-Matter Microstructural Damage and Cognitive Decline in Hemodialysis Patients. ( Andica, C; Aoki, S; Hattori, N; Io, H; Kamagata, K; Miyamoto, N; Motoi, Y; Nakata, J; Saito, A; Shiina, K; Shindo, A; Suzuki, Y; Taniguchi, D; Ueno, Y; Urabe, T; Yamashiro, K, 2021) |
| "This study measured the serum carnitine levels in patients with epilepsy and determined the factors contributing to low carnitine levels." | 7.91 | Serum carnitine levels of children with epilepsy: Related factors including valproate. ( Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2019) |
| "L-carnitine treatment showed opposite effects." | 5.91 | L-carnitine Modulates Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights to Oxidative Stress, Inflammation, Synaptic Plasticity, Liver/brain, and Kidney/brain Axes. ( George, MY; Menze, ET; Morid, OF; Tadros, MG, 2023) |
| "L-carnitine has been shown to exert neuroprotective effects on cerebral ischemia, mainly by improving mitochondrial function and reducing inflammation." | 4.12 | Association Between Plasma L-Carnitine and Cognitive Impairment in Patients with Acute Ischemic Stroke. ( Bu, X; Che, B; Chen, H; He, J; Ju, Z; Peng, H; Wang, A; Xu, T; Zhang, J; Zhang, Y; Zhong, C, 2022) |
| "We examined prospective associations of TMAO, γ-butyrobetaine, crotonobetaine, carnitine, choline, and betaine with risk of cognitive impairment and dementia among older adults aged 65 years and older in the Cardiovascular Health Study (CHS)." | 4.12 | Longitudinal Associations of Plasma TMAO and Related Metabolites with Cognitive Impairment and Dementia in Older Adults: The Cardiovascular Health Study. ( de Oliveira Otto, MC; Fretts, A; Hazen, SL; Lai, HTM; Lee, Y; Lemaitre, RN; Li, XS; Lopez, O; Mozaffarian, D; Nemet, I; Newman, AB; Siscovick, DS; Tang, WHW; Wang, M; Wang, Z, 2022) |
| "Although l-carnitine alleviated white-matter lesions in an experimental study, the treatment effects of l-carnitine on white-matter microstructural damage and cognitive decline in hemodialysis patients are unknown." | 4.02 | Possible Neuroprotective Effects of l-Carnitine on White-Matter Microstructural Damage and Cognitive Decline in Hemodialysis Patients. ( Andica, C; Aoki, S; Hattori, N; Io, H; Kamagata, K; Miyamoto, N; Motoi, Y; Nakata, J; Saito, A; Shiina, K; Shindo, A; Suzuki, Y; Taniguchi, D; Ueno, Y; Urabe, T; Yamashiro, K, 2021) |
| "This study measured the serum carnitine levels in patients with epilepsy and determined the factors contributing to low carnitine levels." | 3.91 | Serum carnitine levels of children with epilepsy: Related factors including valproate. ( Iwayama, H; Kurahashi, H; Numoto, S; Okumura, A, 2019) |
| "L-carnitine treatment showed opposite effects." | 1.91 | L-carnitine Modulates Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights to Oxidative Stress, Inflammation, Synaptic Plasticity, Liver/brain, and Kidney/brain Axes. ( George, MY; Menze, ET; Morid, OF; Tadros, MG, 2023) |
| "Increasing evidence suggest that Alzheimer's disease (AD) is a heterogeneous disorder that includes several subtypes with different etiology and progression." | 1.40 | Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease. ( Cedazo-Mínguez, Á; Cifuentes, A; Ibáñez, C; Lodeiro, M; Simó, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (60.00) | 24.3611 |
| 2020's | 4 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Che, B | 1 |
| Chen, H | 1 |
| Wang, A | 1 |
| Peng, H | 1 |
| Bu, X | 1 |
| Zhang, J | 1 |
| Ju, Z | 1 |
| Xu, T | 1 |
| He, J | 1 |
| Zhong, C | 1 |
| Zhang, Y | 1 |
| de Oliveira Otto, MC | 1 |
| Li, XS | 1 |
| Wang, Z | 1 |
| Siscovick, DS | 1 |
| Newman, AB | 1 |
| Lai, HTM | 1 |
| Nemet, I | 1 |
| Lee, Y | 1 |
| Wang, M | 1 |
| Fretts, A | 1 |
| Lemaitre, RN | 1 |
| Tang, WHW | 1 |
| Lopez, O | 1 |
| Hazen, SL | 1 |
| Mozaffarian, D | 1 |
| Morid, OF | 1 |
| Menze, ET | 1 |
| Tadros, MG | 1 |
| George, MY | 1 |
| Ueno, Y | 1 |
| Saito, A | 1 |
| Nakata, J | 1 |
| Kamagata, K | 1 |
| Taniguchi, D | 1 |
| Motoi, Y | 1 |
| Io, H | 1 |
| Andica, C | 1 |
| Shindo, A | 1 |
| Shiina, K | 1 |
| Miyamoto, N | 1 |
| Yamashiro, K | 1 |
| Urabe, T | 1 |
| Suzuki, Y | 1 |
| Aoki, S | 1 |
| Hattori, N | 1 |
| Peterson, MJ | 1 |
| Geoghegan, S | 1 |
| Lawhorne, LW | 1 |
| Okumura, A | 1 |
| Kurahashi, H | 1 |
| Iwayama, H | 1 |
| Numoto, S | 1 |
| Cassol, G | 1 |
| Godinho, DB | 1 |
| de Zorzi, VN | 1 |
| Farinha, JB | 1 |
| Della-Pace, ID | 1 |
| de Carvalho Gonçalves, M | 1 |
| Oliveira, MS | 1 |
| Furian, AF | 1 |
| Fighera, MR | 1 |
| Royes, LFF | 1 |
| Lodeiro, M | 1 |
| Ibáñez, C | 1 |
| Cifuentes, A | 1 |
| Simó, C | 1 |
| Cedazo-Mínguez, Á | 1 |
| Mapstone, M | 1 |
| Cheema, AK | 1 |
| Fiandaca, MS | 1 |
| Zhong, X | 1 |
| Mhyre, TR | 1 |
| MacArthur, LH | 1 |
| Hall, WJ | 1 |
| Fisher, SG | 1 |
| Peterson, DR | 1 |
| Haley, JM | 1 |
| Nazar, MD | 1 |
| Rich, SA | 1 |
| Berlau, DJ | 1 |
| Peltz, CB | 1 |
| Tan, MT | 1 |
| Kawas, CH | 1 |
| Federoff, HJ | 1 |
| Ciavardelli, D | 1 |
| Piras, F | 1 |
| Consalvo, A | 1 |
| Rossi, C | 1 |
| Zucchelli, M | 1 |
| Di Ilio, C | 1 |
| Frazzini, V | 1 |
| Caltagirone, C | 1 |
| Spalletta, G | 1 |
| Sensi, SL | 1 |
1 review available for carnitine and Cognitive Dysfunction
| Article | Year |
|---|---|
Potential therapeutic implications of ergogenic compounds on pathophysiology induced by traumatic brain injury: A narrative review.
Topics: Animals; Arginine; Brain Injuries, Traumatic; Caffeine; Carnitine; Central Nervous System Stimulants | 2019 |
9 other studies available for carnitine and Cognitive Dysfunction
| Article | Year |
|---|---|
Association Between Plasma L-Carnitine and Cognitive Impairment in Patients with Acute Ischemic Stroke.
Topics: Brain Ischemia; Carnitine; Cognitive Dysfunction; Humans; Inflammation; Ischemic Stroke; Prospective | 2022 |
Longitudinal Associations of Plasma TMAO and Related Metabolites with Cognitive Impairment and Dementia in Older Adults: The Cardiovascular Health Study.
Topics: Animals; Betaine; Carnitine; Choline; Cognitive Dysfunction; Dementia; Medicare; Methylamines; Unite | 2022 |
L-carnitine Modulates Cognitive Impairment Induced by Doxorubicin and Cyclophosphamide in Rats; Insights to Oxidative Stress, Inflammation, Synaptic Plasticity, Liver/brain, and Kidney/brain Axes.
Topics: Acetylcholinesterase; Animals; Antioxidants; Brain; Carnitine; Cognitive Dysfunction; Cyclophosphami | 2023 |
Possible Neuroprotective Effects of l-Carnitine on White-Matter Microstructural Damage and Cognitive Decline in Hemodialysis Patients.
Topics: Administration, Oral; Aged; Aged, 80 and over; Carnitine; Cognitive Dysfunction; Cross-Sectional Stu | 2021 |
An Exploratory Analysis of Potential New Biomarkers of Cognitive Function.
Topics: Aged; Amino Acids; Biomarkers; Carnitine; Cognitive Dysfunction; Cross-Sectional Studies; Female; Ge | 2019 |
Serum carnitine levels of children with epilepsy: Related factors including valproate.
Topics: Adolescent; Body Mass Index; Carnitine; Child; Child, Preschool; Cognitive Dysfunction; Epilepsy; Fe | 2019 |
Decreased cerebrospinal fluid levels of L-carnitine in non-apolipoprotein E4 carriers at early stages of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E4; Arginine; Biomarkers; Carnitine; | 2014 |
Plasma phospholipids identify antecedent memory impairment in older adults.
Topics: Aged; Alzheimer Disease; Asparagine; Biomarkers; Carnitine; Cognitive Dysfunction; Cohort Studies; D | 2014 |
Medium-chain plasma acylcarnitines, ketone levels, cognition, and gray matter volumes in healthy elderly, mildly cognitively impaired, or Alzheimer's disease subjects.
Topics: Aged; Aging; Alzheimer Disease; Carnitine; Cognition; Cognitive Dysfunction; Cohort Studies; Female; | 2016 |